|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG005809428 |
| 003 |
DE-627 |
| 005 |
20230425165327.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2020 xx |||||o 00| ||und c |
| 035 |
|
|
|a (DE-627)CTG005809428
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ACTRN12616001312437
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)None
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a und
|
| 245 |
1 |
0 |
|a Plasma lipoproteins in coronary artery disease.
|b Redox signaling, Beta 2 Glycoprotein 1 and plasma lipoproteins in coronary artery disease.
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-09-2016, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Coronary artery disease;Association of plasrma lipoproteins in atherosclerotic and atherothrombotic coronary artery disease.; Coronary artery disease Association of plasrma lipoproteins in atherosclerotic and atherothrombotic coronary artery disease.;Cardiovascular - Coronary heart disease
|
| 650 |
|
4 |
|a Study Type: Observational
|
| 650 |
|
4 |
|a Recruitment Status: Active, not recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2020) vom: 13. Jan.
|
| 773 |
1 |
8 |
|g year:2020
|g day:13
|g month:01
|
| 856 |
4 |
0 |
|u https://anzctr.org.au/ACTRN12616001312437.aspx
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2020
|b 13
|c 01
|
Klinische Studie